<DOC>
	<DOCNO>NCT00344851</DOCNO>
	<brief_summary>Current research show use diabetes management practice aim reduce insulin resistance hyperinsulinemia ( weight reduction administration oral antidiabetic drug ) woman PCOS improve glucose lipid metabolism also reverse testosterone abnormality restore menstrual cycle . A new medicine call exenatide ( Byetta ) find reduce body weight , well , improve abnormal glucose metabolism diabetic . This randomized study compare Exenatide ( Byetta ) extend release metformin ( Fortamet ) combination therapy ( Byetta Fortamet ) menstrual cyclicity , hormone profile metabolic profile 24-week period woman PCOS .</brief_summary>
	<brief_title>Exenatide Metformin Therapy Overweight Women With PCOS</brief_title>
	<detailed_description>Objectives : The objective present proposal compare clinical , endocrine metabolic effect therapy exenatide metformin alone , combination therapy woman PCOS . This study serve pilot investigation open perspectives future investigation combine insulin-sensitizing drug different mechanism action patient PCOS , especially one standard treatment metformin less effective . Subjects : 60 oligomenorrheic overweight/obese ( BMI &gt; 27 ) woman meet criterion PCOS ( age 18-40 ) · six few menses /year amenorrheic· clinical laboratory evidence hyperandrogenism ( hirsutism elevate testosterone ( T ) ) · PCOS ovary ultrasound ( need meet criterion 1 either 2 3 [ ] ) Inclusion/Exclusion Criteria : Major EXCLUSION CRITERIA – FEMALE1 ) uncorrected endocrinopathy- hyperprolactinemia , hyper- hypothyroidism , congenital adrenal hyperplasia2 ) presence overt diabetes impair glucose tolerance3 ) alteration hepatic renal function4 ) use hormonal medication , insulin sensitizer medication interfere carbohydrate metabolism least 8 weeks5 ) Any medical condition , judgment investigator may interfere absorption , distribution , metabolism excretion drug6 ) Simultaneous participation another clinical trial7 ) Known active substance abuse include tobacco alcohol . ( &gt; 10 cigarettes/day ) 8 ) Refusal inability comply protocol9 ) patient desire pregnancy , pregnant , breastfeed Study Design : Balanced randomize parallel group clinical study 3 treatment arm : metformin ( 1000 mg BID ) ; exenatide ( 10 mcg BID ) combine ( metformin 1000 mg BID ; exenatide 10 mcg BID ) therapy 24 week . Efficacy Measures : Primary- Menstrual Cyclicity ( # menses/ 24 week ) Secondary-BMI , WHR , FAI ( T/SHBG ) , DHEAS , lipid , insulin resistance- ( HOMA composite insulin sensitivity index [ SIOGTT ) , pancreatic ß-cell function ( correct insulin response [ CIRgp ] insulinogenic index [ IGI ] ) . Safety : For safety , subject enter study evaluable . Subjects monitor safety assessment adverse event , physical exam , vital sign laboratory value . Statistical methods/analysis : The measurement menstrual frequency involve nominal data ( patient with/without regular cycle pre vs post-treatment analyze use McNemar test ( complex chi square pair data ) . For analysis , data interval , parameter , androgen , lipid , insulin sensitivity , etc . evaluate use SS/Treatment x Trials ( pre/post ) analyse variance ( ANOVA ) . This repeated measure design allow u determine treatment drug effect significantly different control individual patient difference Study Drug Regimens : Exenatide5 ug bid - 4 weeks10 ug bid - 20 week ( end study ) Metformin500 mg qd 2 weeks500 mg bid 2 week 500 mg , 1000 mg pm- 2 weeks1000 mg bid –18 week ( end study ) Exenatide plus MetforminExenatide- 5 ug bid-4 weeksMetformin 500 qd 2 week , 500 mg bid 2 weeksExenatide- 10 ug –20 week ( end study ) Metformin-500 mg , 1000 mg pm- 2 week – 1000 bid 18 week ( end study ) ** Metformin may adjust discretion physician level tolerable patient tolerate full dose metformin combination exenatide ( combination therapy )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Overweight/obese woman ( BMI &gt; 27 ) 1 . Must six few menses /year amenorrheic 2 . Have either clinical laboratory evidence hyperandrogenism ( hirsutism elevate testosterone ( T ) ) /or PCOS ovary ultrasound uncorrected endocrinopathy hyperprolactinemia , hyper hypothyroidism , congenital adrenal hyperplasia presence overt diabetes alteration hepatic renal function use hormonal medication , insulin sensitizer medication interfere carbohydrate metabolism least 8 week Known active substance abuse include tobacco alcohol . Pregnancy , breastfeed desire pregnancy study interval ( 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>menstrual cyclicity</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>body fat distribution</keyword>
	<keyword>pancreatic ß-cell function</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>liver function test</keyword>
</DOC>